Evelo Biosciences, Inc (EVLO)

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 12 by Evelo Biosciences, Inc. (Nasdaq: EVLO), please note that in the first sentence of the First Quarter 2022 Financial Results (Unaudited) section, the dates should be “As of March 31, 2022, cash and cash equivalents were $39.6 million, as compared to cash and cash equivalents of $68.4 million as of December 31, 2021,” not December 31, 2021 and March 31, 2021. The corrected release f

Evelo Biosciences (NASDAQ:EVLO) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what ...

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the first quarter 2022. “This quarter we reported positive data for EDP1815 in psoriasis in three key areas: effects on systemic inflammatory cytokine markers; depth and duration of response at 6-month follow-up post dosing; and increased target site e

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX ...

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals ...

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that John Maraganore, Ph.D., founder and longtime former CEO of Alnylam Pharmaceuticals, and Tassos Gianakakos, the longtime former CEO of MyoKardia, have joined Evelo as strategic advisors. “We are thrilled to welcome both John and Tassos as strategic advisors to Evelo,” said Simba Gill, Ph.D.,

The financial media loves to get predictions from experts about where they think a given stock market index is headed. Some experts look at technical analysis patterns, others look at valuation metrics, others apply a broad macro view of the economy..

Evelo Biosciences Inc(NASDAQ: EVLO) willput the EDP1867 program on holdafter completing a Phase 1 clinical trial in ...

–Guidance on registration trials for EDP1815 in psoriasis expected in 3Q 2022––Data from initial cohort of patients in Phase 2 trial of EDP1815 in atopic dermatitis expected 1Q 2023––Faster release capsule cohort to be added to on-going Phase 2 trial of EDP1815 in atopic dermatitis; data expected 1H 2023– CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally deliv

CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Jose-Carlos Gutiérrez-Ramos, Ph.D., and Tonya Williams, J.D., to its Board of Directors. “We are delighted to welcome Jose-Carlos back to our Board. He is one of the world's preeminent drug discovery and immunology leaders, and has vast experience across both large pharmaceuti

CAMBRIDGE, Mass., March 26, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today presented a late-breaking oral abstract on data from a Phase 2 trial of EDP1815 in psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting, being held March 25-29 in Boston, Massachusetts. “We are proud to join the dermatology community at

Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its ...

U.S. stocks traded higher toward the end of trading, with the Nasdaq composite gaining over 150 points on Thursday. The Dow traded up ...

Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) stock increased by 26.3% to $1.73 during Thursday's regular session. ...

EVLO earnings call for the period ending December 31, 2021.

In the Q4 earnings release,Evelo Biosciences Inc(NASDAQ: EVLO) shared results from an ongoing Phase 1 single-center trial in ...

U.S. stocks traded higher midway through trading, with the Dow Jones jumping 250 points on Thursday. The Dow traded up 0.75% to ...

Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 37.7% to $4.64. Emclaire Financial Corp (NASDAQ: EMCF) shares ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Novartis Announces FDA ...

Evelo Biosciences (NASDAQ:EVLO) reported its Q4 earnings results on Thursday, March 24, 2022 at 06:00 AM. Here's what ...

–Oral presentation on EDP1815 Phase 2 data in psoriasis accepted in late-breaking abstract session at AAD on Saturday, March 26, 2022 ––Positive data reported on faster release capsule––Phase 2 data from EDP1815 in atopic dermatitis on-track for 1H 2023 readout––Management to host conference call at 8:30 a.m. ET– CAMBRIDGE, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of ora

Companies Reporting Before The Bell • iHuman (NYSE:IH) is likely to report earnings for its fourth quarter. • ...

Evelo Biosciences (NASDAQ:EVLO) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need ...

Biotech stocks rebounded along with the broader market in the week endingMarch 18, as risk appetite returned. Multiple conference ...

Evelo Biosciences (NASDAQ:EVLO) will host a conference call at 08:30 AM ET on March 24, 2022, to discuss Q4 2021 earnings results. How ...

CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 24, 2022 to report its fourth quarter and full year 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-7

CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a virtual event titled, “The Future: A no regrets treatment for all stages of psoriasis and broader inflammatory disease.” The event will be held virtually on Friday, March 11, 2022, beginning at 8:00 a.m. ET. During the event, mem

Evelo Biosciences (EVLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that Simba Gill, Ph.D., Chief Executive Officer of Evelo, will participate in a panel discussion titled “GI/Microbiome” at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9th, 2022 at 10:30 a.m. ET. A live audio webcast of the panel

Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to ad